No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SAGE240816C17500
- 0.25
- -0.50-66.67%
15min DelayClose Jul 24 15:59 ET
0.25High0.25Low
0.25Open0.75Pre Close10 Volume59 Open Interest17.50Strike Price250.00Turnover159.67%IV71.00%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.1387Delta0.0529Gamma41.52Leverage Ratio-0.0199Theta0.0008Rho5.76Eff Leverage0.0058Vega
Intraday
- 5D
- Daily
News
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Wedbush Adjusts Sage Therapeutics' PT to $9 From $15, Maintains Neutral Rating
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics' Stock Dives as Failed Trial Hits Biogen Collaboration
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
SAGE Therapeutics: Hold Rating Following SAGE-324 Clinical Trial Setback
Comments
$Sage Therapeutics(SAGE.US$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint
4
$Sage Therapeutics(SAGE.US$ what just happened
$Sage Therapeutics(SAGE.US$ what’s happening
1
$Sage Therapeutics(SAGE.US$ Sage Therapeutics Says Phase 2 SURVEYOR Study Strengthens Cognitive Impact Of Huntington's Disease! For Participants With Hd Got Dalzanemdor or Placebo, Dalzanemdor Was Generally Well-Tolerated With No New Safety Signals Observed
1
Read more
TrytosaveabitOP : Sage Therapeutics Inc: Do Not Plan to Conduct Further Clinical Development of Sage-324 in Et
买跌不追涨 : Can't go short
TrytosaveabitOP 买跌不追涨: Sorry. I won’t go short. Don’t believe in it personally! GL
买跌不追涨 TrytosaveabitOP: I also seldom go short